Updated hourlyHourly refreshTue, Oct 27, 2026
Press Release Database
Recent press releases, indexed by topic.
AI · Healthcare
Rising cancer incidence and R&D investment are expanding oncology trials. AI can improve recruitment, trial design and data management, while partnerships and novel therapies spur competition.
Rising cancer incidence and R&D investment are expanding oncology trials. AI can improve recruitment, trial design and data management, while partnerships and novel therapies spur competition.
Sep 24 · 09:09·GlobeNewswire
Automotive · Biotech & pharma
Expanding CAR-T and bispecific use is increasing CRS cases, creating opportunities in early diagnosis, preventive immunomodulators, outpatient care and biosimilar IL-6 therapies.
Expanding CAR-T and bispecific use is increasing CRS cases, creating opportunities in early diagnosis, preventive immunomodulators, outpatient care and biosimilar IL-6 therapies.
Sep 24 · 09:04·GlobeNewswire
Biotech & pharma
Rising surgeries and opioid safety concerns are accelerating multimodal, non-opioid pain care, creating opportunities for safer parenteral drugs and novel delivery systems.
Rising surgeries and opioid safety concerns are accelerating multimodal, non-opioid pain care, creating opportunities for safer parenteral drugs and novel delivery systems.
Sep 24 · 09:03·GlobeNewswire
AI · Healthcare
AI adoption is accelerating drug discovery, precision medicine, diagnostics and clinical trials, fueled by expanding health data, software demand and pharma-tech partnerships
AI adoption is accelerating drug discovery, precision medicine, diagnostics and clinical trials, fueled by expanding health data, software demand and pharma-tech partnerships
Sep 24 · 09:00·GlobeNewswire
Finance · Healthcare
OXFORD, United Kingdom and BURLINGTON, Mass., Sept. 24, 2026 -- Scancell Holdings plc (AIM: SCLP) (“Scancell”, or the “Company”), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers, announced today that, further to its announcement on 23 July 2026 regarding the planned merger with Neuphoria Therapeutics Inc. (“Neuphoria”) and financing to conduct the registrational Phase 3 study for iSCIB1+ and a proposed listing on Nasdaq (the “Merger and Financing Announcement”), it has entered into a loan agreement (the “Loan Agreement”) with certain funds and accounts managed by BlackRock (the “Lender”), for a loan facility of up to US$25,000,000 (the “Loan Facility”).
Sep 24 · 05:00·GlobeNewswire
Finance · Healthcare
Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Half-Year and Second Quarter financial results on September 28, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on September 28, 2026.
Sep 24 · 05:00·GlobeNewswire
Finance · Healthcare
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place on October 23-27, 2026, in Madrid, Spain.
Sep 24 · 00:00·GlobeNewswire
Healthcare · Biotech & pharma
- Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanced NSCLC - - Milestone marks second Phase 3 study of setidegrasib initiated within six months - TOKYO, Sept. 23, 2026 --...
Sep 23 · 23:30·PR Newswire
Finance · Biotech & pharma
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2026 financial results on Tuesday, November 3, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Sep 23 · 20:45·GlobeNewswire
Finance · Biotech & pharma
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the “Investors” page on its website.
Sep 23 · 20:45·GlobeNewswire
Finance · Healthcare
SAN DIEGO, Sept. 23, 2026 -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its intention to offer, subject to market and other...
Sep 23 · 20:32·PR Newswire
Healthcare · Biotech & pharma
Featuring Serina Therapeutics’ CEO - Thursday, September 24, 2026
Sep 23 · 20:18·GlobeNewswire